Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by nine individuals on April 12, 2012, through the Company's ShareReward Plan. The purchase price was 1,403.9264 pence per Ordinary Share. Each individual acquired 9 shares via the personal contribution element and 9 shares via the matching element (Company contribution). No other material changes to the company's operations or financial position are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of director shareholdings under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the share price of 1,403.9264 pence per Ordinary Share on April 12, 2012.
- Confirm the total number of shares acquired by each listed director (18 shares per person: 9 personal + 9 matching).
- Review the full list of participating directors: Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr E J Gray, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, and Mrs V A Whyte.
- Note that this filing contains no financial performance metrics; refer to Form 20-F for comprehensive financial data.